{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-24-000126","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.890105+00:00","generated_at":"2026-05-31T09:49:56.497806+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa Q2 net loss widens to $43.8M; cash $294.8M; ORX750 data expected 2H 2024","bullets":["Net loss $43.8M vs $24.9M YoY; prior Q2 included $24.1M tax benefit.","Cash $294.8M; funds operations into mid-2026; raised $107.3M net in public offering.","ORX750 Phase 1 initiated; PoC data in sleep-deprived volunteers expected 2H 2024 using MWT.","ORX142 nominated as development candidate; IND-enabling activities underway.","SerpinPC registrational program progressing; PRESent-2 Part 1 interim analysis planned 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-24-000126","json":"https://secwatch.observer/filing/0001847903-24-000126.json","markdown":"https://secwatch.observer/filing/0001847903-24-000126.md","text":"https://secwatch.observer/filing/0001847903-24-000126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000126/0001847903-24-000126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000126/cnta-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:49:56.497806+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}